血管内卒中治疗的影像学特征及安全性有效性:个体患者水平数据的Meta分析
该Meta分析汇总7项随机试验的1764例前循环大血管闭塞急性缺血性卒中患者,比较血管内取栓(EVT)与标准药物治疗。EVT组90天功能预后优于对照组(校正cOR 2.00,95%CI 1.69-2.38,p<0.0001),在广泛基线影像类别中均一致;但ASPECTS 0-4及MCA供血区受累>33%患者中EVT组症状性颅内出血更高。
要点
- EVT组90天功能预后优于标准药物治疗(校正cOR 2.00,95%CI 1.69-2.38,p<0.0001)。
- ASPECTS 0-4患者中症状性颅内出血EVT组19%(10/52)vs对照组5%(3/66),校正cOR 3.94(95%CI 0.94-16.49),交互p=0.025。
- MCA供血区受累>33%患者中症状性颅内出血EVT组14%(15/108)vs对照组4%(4/113),cOR 4.17(95%CI 1.30-13.44),交互p=0.012。
核心结论
- EVT在广泛基线影像类别中90天功能预后优于标准药物治疗,包括梗死累及MCA供血区>33%或ASPECTS<6的患者,但这些患者中EVT组症状性颅内出血风险高于对照组。
- 该分析为基线大面积梗死患者潜在使用EVT提供了初步证据。
研究设计与样本
- HERMES协作组在PubMed检索2010年1月1日至2017年10月31日发表的7项比较EVT与标准药物治疗的血管内卒中随机试验,进行个体患者水平数据的Meta分析。
- 仅纳入要求血管影像识别近端前循环缺血性卒中患者、且EVT组主要使用支架取栓器或第二代神经血栓切除装置的试验。
- 采用Cochrane手册方法学评估偏倚风险。
- 中心研究者对除卒中侧别外的临床信息设盲,按ASPECTS或MCA供血区受累>33%、血栓体积、高密度及侧支状态对基线影像特征分类。
- 主要终点为随机化后90天改良Rankin量表(mRS)评分的神经功能残疾。
主要发现
- 总体治疗效应有利于EVT(mRS向更好预后偏移的校正共同比值比[cOR] 2.00,95%CI 1.69-2.38;p<0.0001)。
- 90天死亡率EVT组14.7% vs 对照组17.3%(p=0.15),症状性颅内出血3.8% vs 3.5%(p=0.90),实质性血肿2型5.6% vs 4.8%(p=0.52),两组间均无显著差异。
- 90天死亡率和实质性血肿2型均未观察到基线影像特征对治疗效应的修饰作用。
- ASPECTS 0-4患者中,症状性颅内出血EVT组10/52(19%)vs 对照组3/66(5%),校正cOR 3.94(95%CI 0.94-16.49;交互p=0.025)。
- MCA供血区受累>33%患者中,症状性颅内出血EVT组15/108(14%)vs 对照组4/113(4%),cOR 4.17(95%CI 1.30-13.44;交互p=0.012)。
关键数值与推荐
- 主要终点采用混合效应有序逻辑回归校正年龄、性别、入院NIHSS评分、静脉阿替普酶及发病至随机化时间。
- 使用交互项检验基线影像分类是否修饰治疗与结局的关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 该Meta分析由HERMES执行委员会前瞻性设计但未注册。
- THRACE试验采用非盲法评估随机化后90天结局且主要使用MRI作为基线影像工具。
- ASPECTS 0-4患者中症状性颅内出血的校正cOR 3.94(95%CI 0.94-16.49)置信区间宽且跨1。
- 该分析为基线大面积梗死患者潜在使用EVT提供了初步证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence regarding whether imaging can be used effectively to select patients for endovascular thrombectomy (EVT) is scarce. We aimed to investigate the association between baseline imaging features and safety and efficacy of EVT in acute ischaemic stroke caused by anterior large-vessel occlusion. METHODS: In this meta-analysis of individual patient-level data, the HERMES collaboration identified in PubMed seven randomised trials in endovascular stroke that compared EVT with standard medical therapy, published between Jan 1, 2010, and Oct 31, 2017. Only trials that required vessel imaging to identify patients with proximal anterior circulation ischaemic stroke and that used predominantly stent retrievers or second-generation neurothrombectomy devices in the EVT group were included. Risk of bias was assessed with the Cochrane handbook methodology. Central investigators, masked to clinical information other than stroke side, categorised baseline imaging features of ischaemic change with the Alberta Stroke Program Early CT Score (ASPECTS) or according to involvement of more than 33% of middle cerebral artery territory, and by thrombus volume, hyperdensity, and collateral status. The primary endpoint was neurological functional disability scored on the modified Rankin Scale (mRS) score at 90 days after randomisation. Safety outcomes included symptomatic intracranial haemorrhage, parenchymal haematoma type 2 within 5 days of randomisation, and mortality within 90 days. For the primary analysis, we used mixed-methods ordinal logistic regression adjusted for age, sex, National Institutes of Health Stroke Scale score at admission, intravenous alteplase, and time from onset to randomisation, and we used interaction terms to test whether imaging categorisation at baseline modifies the association between treatment and outcome. This meta-analysis was prospectively designed by the HERMES executive committee but has not been registered. FINDINGS: Among 1764 pooled patients, 871 were allocated to the EVT group and 893 to the control group. Risk of bias was low except in the THRACE study, which used unblinded assessment of outcomes 90 days after randomisation and MRI predominantly as the primary baseline imaging tool. The overall treatment effect favoured EVT (adjusted common odds ratio [cOR] for a shift towards better outcome on the mRS 2·00, 95% CI 1·69-2·38; p<0·0001). EVT achieved better outcomes at 90 days than standard medical therapy alone across a broad range of baseline imaging categories. Mortality at 90 days (14·7% vs 17·3%, p=0·15), symptomatic intracranial haemorrhage (3·8% vs 3·5%, p=0·90), and parenchymal haematoma type 2 (5·6% vs 4·8%, p=0·52) did not differ between the EVT and control groups. No treatment effect modification by baseline imaging features was noted for mortality at 90 days and parenchymal haematoma type 2. Among patients with ASPECTS 0-4, symptomatic intracranial haemorrhage was seen in ten (19%) of 52 patients in the EVT group versus three (5%) of 66 patients in the control group (adjusted cOR 3·94, 95% CI 0·94-16·49; pinteraction=0·025), and among patients with more than 33% involvement of middle cerebral artery territory, symptomatic intracranial haemorrhage was observed in 15 (14%) of 108 patients in the EVT group versus four (4%) of 113 patients in the control group (4·17, 1·30-13·44, pinteraction=0·012). INTERPRETATION: EVT achieves better outcomes at 90 days than standard medical therapy across a broad range of baseline imaging categories, including infarcts affecting more than 33% of middle cerebral artery territory or ASPECTS less than 6, although in these patients the risk of symptomatic intracranial haemorrhage was higher in the EVT group than the control group. This analysis provides preliminary evidence for potential use of EVT in patients with large infarcts at baseline. FUNDING: Medtronic.
引用
- Román LS, Menon BK, Blasco J, et al. Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data. Lancet Neurol. 2018. PMID: 30264728. doi:10.1016/S1474-4422(18)30242-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。